Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cyclin-dependent kinase 4 (Homo sapiens (Human)) | BDBM148254 (US8962630, 63) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 8 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 4 (Homo sapiens (Human)) | BDBM148264 (7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)p...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 4 (Homo sapiens (Human)) | BDBM148218 (US8962630, 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 26 | n/a | n/a | n/a | n/a | 7.5 | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148210 (US8962630, 18) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148203 (US8962630, 11) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148238 (US8962630, 47) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60E+3 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148210 (US8962630, 18) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148226 (US8962630, 35) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.90E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148203 (US8962630, 11) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 3.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148226 (US8962630, 35) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 4.70E+3 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148232 (US8962630, 41) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 4.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148199 (US8962630, 8) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 8.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148238 (US8962630, 47) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148202 (US8962630, 10A) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.20E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148277 (US8962630, 87) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.30E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148199 (US8962630, 8) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.40E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 2 (Homo sapiens (Human)) | BDBM148202 (US8962630, 10A) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.40E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148232 (US8962630, 41) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.48E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148194 (US8962630, 1) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148264 (7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148268 (US8962630, 78) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148276 (US8962630, 86) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148218 (US8962630, 26) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148206 (US8962630, 14) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148283 (US8962630, 95) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148224 (US8962630, 33) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148248 (US8962630, 57) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148247 (US8962630, 56) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148261 (US8962630, 71) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148213 (US8962630, 21) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148235 (US8962630, 44) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148237 (US8962630, 46) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148220 (US8962630, 29) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148269 (US8962630, 79) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148254 (US8962630, 63) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148227 (US8962630, 36) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148287 (US8962630, 101) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148288 (US8962630, 103) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148259 (US8962630, 69) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148281 (US8962630, 92) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148285 (US8962630, 99) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148279 (US8962630, 90) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148258 (US8962630, 68) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148217 (US8962630, 25) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148201 (US8962630, 10) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148274 (US8962630, 84) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148200 (US8962630, 9) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148198 (US8962630, 7) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148219 (US8962630, 27) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cyclin-dependent kinase 1 (Homo sapiens (Human)) | BDBM148215 (US8962630, 23) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | >1.50E+4 | n/a | n/a | n/a | n/a | n/a | 25 |
Novartis AG US Patent | Assay Description A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ... | US Patent US8962630 (2015) BindingDB Entry DOI: 10.7270/Q2RJ4H6C | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 205 total ) | Next | Last >> |